The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | iStopMM: benefits and harms of screening for myeloma precursor disease
Sigrun Thorsteinsdottir, MD, National University Hospital of Iceland, Reykjavik, Iceland, discusses the potential impact of the ongoing iStopMM study assessing the benefits and harms of screening the general population for smoldering multiple myeloma (NCT03327597). Dr Thorsteinsdottir explains that if the study finds that screening positively impacts overall survival (OS) and quality of life (QoL), it could be introduced into clinical practice. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
